A validated biomarker risk score based on the expression of 34 genes improves risk stratification of patients with meningioma, including prediction of post-operative radiotherapy benefit.
This is a preview of subscription content, log in via an institution to check access.
References
Chen, W. C. et al. Radiotherapy and radiosurgery for meningiomas. Neurooncol. Adv. 5, i67–i83 (2023). A review that summarizes the literature on meningioma classification and treatment.
Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649–659 (2022). A study of meningioma molecular groups using DNA-methylation profiling.
Choudhury, A. et al. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 25, 520–530 (2023). A study of meningioma molecular subgroups using DNA-methylation profiling.
Patel, A. J. et al. Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. Proc. Natl Acad. Sci. USA 116, 21715–21726 (2019). A study of meningioma molecular groups using RNA sequencing.
Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119–125 (2021). A paper reporting a meningioma molecular classification using DNA-methylation profiling, RNA sequencing, copy-number variants and somatic short variants.
Louis, D. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231–1251 (2021). A paper summarizing the 2021 World Health Organization classification of central nervous system tumors.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Chen, W. C. et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat. Med. https://doi.org/10.1038/s41591-023-02586-z (2023).
Rights and permissions
About this article
Cite this article
Meningioma risk stratification with a targeted gene-expression biomarker. Nat Med 29, 3020–3021 (2023). https://doi.org/10.1038/s41591-023-02642-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02642-8
- Springer Nature America, Inc.